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Abstract
Purpose: To evaluate the clinical outcomes and patterns of failure in patients with nasopharyngeal carcinoma
(NPC) treated with intensity modulated radiotherapy (IMRT) in Northwest China.
Methods and materials: From January 2006 to December 2009, 138 NPC patients were treated at Xijing Hospital.
Of them, 25 cases with stage I-II received IMRT only, 113 cases with stage III-IVb received IMRT plus accomplished
platinum-based chemotherapy. The IMRT prescribed dose was PTV 68-74 Gy to gross disease in nasopharynx and
66-72 Gy to positive lymph nodes in 30-33 fractions, and high risk and low risk region PTV was 60-63 Gy and
50.4~56 Gy in 30~33 and 28 fractions respectively. Plasma Epstein Barr virus (EBV) DNA load was measured before
treatment. The clinical toxicities, outcomes and patterns of failure were observed.
Results: The median follow up time was 23 months (range 2 to 53 months). EBV infection positive was only 15.9%.
Overall disease failure developed in 36 patients, 99% belonged to stage III/IV disease. Among these, there were 26
distant metastases, 6 local recurrence, and 4 regional recurrence. The 3-year local control rate(LCR), distant
metastasis-free survival (MFS), disease-free survival (DFS) and the overall survival (OS) was 93.9%, 79.5%, 70% and
83.1% respectively. Multivariate analyses revealed that age and anemia pre-radiotherapy were independent
predictors for OS.
Conclusion: IMRT with or without chemotherapy can improve the long term survival of NPC patients in Northwest
China. Distant metastasis becomes the main cause of treatment failure. Age and anemia before radiotherapy were
the main prognosis factors of NPC patients.
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Introduction
Nasopharyngeal carcinoma (NPC) presents a remarkably
distinctive ethnic and geographic distribution, it is a rare
malignancy in northwestern China but is more common
in Southern China or Southeast Asia. The Epstein Barr
virus (EBV) infection is frequently associated with the
patients in Southern China [1,2]. NPC is highly sensitive
to radiation, early stage NPC is often curable by
radiation, and radiotherapy is the mainstay treatment
strategy. However approximately 70% of newly diag-
nosed NPC patients present with stage III or IV disease,
which are prone to suffer from locoregional recurrence
or distant metastases after radiotherapy alone [3-5].
Hence, treatment of advanced NPC usually requires
combined chemoradiation therapy. Forepart randomized
trials displayed adjuvant chemotherapy delivered with
conventional radiotherapy failed to improve NPC overall
survival [6], those results were subsequently confirmed
by a number of studies [7]. Although the neoadjuvant
chemotherapy has demonstrat e di m p r o v e dl o c o r e g i o n a l
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survival has not yet to be confirmed [8]. In a word, it
lacks powerful evidences to demonstrate overall survival
benefits from chemotherapy [9], even through rando-
mized trials of concurrent chemoradiation therapy for
advanced NPC have showed a progression-free survival
[5,10-12].
In pattern of conventional 2 dimensional radiotherapy,
many factors are associated with the NPC prognosis,
including age, gender, anemia, TNM stage, histopathol-
ogy, radiation dose, radiation field, and combined man-
ner of chemotherapy [1,13,14]. Nasopharynx is
surrounded by more radiosensitive structures, simulta-
neity nasopharyngeal carcinoma cell is easy to infiltrate
and spread towards surrounding normal organs. Those
result in NPC irradiation target volumes are very irregu-
lar, conventional radiotherapy adopted lateral opposing
fields for NPC rarely achieves the prerequisite dose and
precision to tumor targets. On account of advancement
of radicalized technology, especially IMRT has been
applied, the limitation of conventional 2D radiotherapy
for NPC can be overcome by IMRT, synchronously, tra-
ditional prognostic factors seem to change stealthily.
IMRT can contribute to a high dose to the tumor while
keeping down normal tissue complications by limiting
radiation dose to normal tissues, the different organs
can receive different fractional dose at the same fraction
of treatment, results in the best radicalized biological
effectiveness [15,16]. Several series reported showed
excellent local control of more than 90% in NPC
received with IMRT [16,17], even among patients with
advanced T3-4 diseases [18]. Especially the phase II
0225 Trial confirmed the excellent outcomes, IMRT
with or without chemotherapy in the treatment of NPC
achieved the almost indistinctive benefit in local pro-
gression-free and overall survivals [19].
Even though numerous favourable reports for NPC
have focus on IMRT, IMRT can unfold a novel thresh-
old for NPC, the result still need to be confirmed in dif-
ferent region. The present retrospective study exhibited
clinical outcomes and patterns of failure in NPC
patients treated with IMRT in Northwest China.
Materials and methods
All patients were native and resided in northwest China,
consisted of 138 consecutive untreated patients who had
histologically confirmed NPC before radiotherapy
between January 2006 and December 2009. Stage I-IVb
NPC histologically classified by the World Health Orga-
nisation (WHO) system [20]: Stage I, representing squa-
mous cell carcinoma, is similar to carcinomas arising
from other sites of head and neck. Stage II is charac-
terised as non-keratinizing carcinoma. Stage III, repre-
senting undifferentiated carcinoma. TNM classification
system by AJCC [21,22]. Patients who had evidence of
distant metastasis were remove from this treatment
choice. Of those patients. 25 cases with stage I-II
received IMRT only, 113 cases with stage III-IVb
received IMRT plus accomplish e dp l a t i n u m - b a s e dc h e -
motherapy. Patient characteristics and treatment factors
are shown in Table 1.
Pretreatment evaluations consisted of complete physi-
cal examination, nasopharyngoscopy, Magnetic reso-
nance imaging (MRI) or computed tomography (CT)
imaging of the nasopharyngeal region and neck. Posi-
tron emission tomography (PET) was optional. The rou-
tine examine included chest X-ray, complete blood
Table 1 Patient and disease characteristics
Patients
Characteristics No. %
Age, years
Median 46
Range 11-72
Sex
Male 104 75.4
Female 34 24.6
EBV infection
< 1000 copy 116 84.1
≥1000 copy 22 15.9
Tumor factors
WHO histology
I 2 1.5
II 99 71.7
III 37 26.8
AJCC T category
T1-2 100 72.5
T3-4 38 27.5
AJCC N category
N0-1 78 56.5
N2-3 60 43.5
AJCC stage
I 6 4.4
II 19 13.8
III 64 46.4
IVa 39 28.3
IVb 10 7.3
Treatment factors
IMRT alone 25 18.1
IMRT + chemotherapy 113 81.9
Chemotherapy manner
Neoadjuvant chemotherapy 43 31.2
Concurrent chemotherapy 18 13.0
Concurrent +Adjuvant 52 37.7
WHO = World Health Organization.
AJCC = American joint committee on carcinoma
Concurrent +Adjuvant = Concurrent +Adjuvant chemotherapy
Wang et al. Radiation Oncology 2012, 7:2
http://www.ro-journal.com/content/7/1/2
Page 2 of 7count, serology of Epstein-Barr virus (EBV), renal and
liver function tests. Anaemia assumed the HBC value: <
120 g/L in males, < 110 g/L in females. Additional
investigations were performed for those with suspicious
findings or abnormal biochemical profile.
Methods
IMRT
All patients were immobilized in the supine position
with thermoplastic masks. Contrast-enhanced planning
computed tomography (CT) scans with a 3 mm slide
thickness were then obtained, with coverage from the
skull vertex to 2 cm below the clavicles. MRI/CT images
was performed for all patients for accurate delineation
of tumor volumes and critical structures. The primary
tumor and upper neck above the bottom of hyoid bone
was treated with IMRT techniques using seven coplanar
beams, inverse treatment planning was performed using
the Eclipse treatment-planning system with simulated
annealing. IMRT was delivered by using a simultaneous-
integrated boost (SIB) technique [23].
T h eg r o s st u m o rv o l u m e( G T V )i n c l u d e st h ep r i m a r y
nasopharyneal tumor (GTVnx) and involved lymph
nodes (GTVnd) as demonstrated by imaging and physi-
cal examinations. The high-risk clinical tumor volume
(CTV-1) included GTV plus 5 mm margin and encom-
passed the entire nasopharyngeal mucosa plus 5 mm
submucosal volume. The CTV2 covers the CTV1 and
area at risk, including posterior third of nasal cavity and
maxillary sinus, pterygopalatine fossa, posterior ethmoid
sinus, parapharyngeal space, skull base, clivus or based
on tumor invasion. The CTV3 covers lower risk lym-
phatic levels. The planning target volume (PTV) was
created based on each CTVs with an additional 3-5 mm
margin, accounting for organ motion/daily treatment
set-up uncertainties. In areas where the GTV or the
CTV was adjacent to critical normal structures (ie,
brainstem), a smaller margin was delineated.
The prescribed dose was 68-74 Gy to gross disease
PTV in nasopharynx and 66-72 Gy to positive lymph
nodes in 30-33 fractions, and the prescribed dose to
high risk vs. low risk region PTV was 60-63 Gy vs.
50.4~56 Gy in 30~33 and 28 fractions respectively.
Treatment will be delivered once daily, 5 fractions per
week. The dose received by each OAR should be no
more than its tolerance limits. For patients given induc-
tion chemotherapy, the target delineations were based
on the pre-chemotherapy extent as shown on the CT/
MRI images.
Chemotherapy
Except 25 patients in stage I-II, other 113 patients in
stage III-IVb had additional accomplished platinum-
based chemotherapy (Table 1). Various sequences and
regimens of cytotoxic drugs (all cisplatin based) had
been used. Neoadjuvant chemotherapy was given to 43
patients, who were in stage III~IVb, mainly consisted of
2~3 cycles of PF (cisplatin 30 mg/m2/d IV for 3 days, 5-
FU 800~1000 mg/m2 IV in d1-d5) or TP regimen (Doc-
etaxel 75 mg/m2 IV in d1, cisplatin 30 mg/m2/d IV for
3 days) at a 2 week interval prior to the initiation of RT
treatment. Concurrent chemotherapy only was given to
18 patient mainly with cisplatin 80-100 mg/m2 on day
1-3 at 3 weekly intervals during the course of RT. Con-
current and adjuvant chemotherapy were given to 52
patients according to NPC-9901 Trial. Patients who
received neoadjuvant chemotherapy were not offered
adjuvant chemotherapy.
Follow-up
All patients were evaluated weekly during treatment
period, after the completion of their treatment, fol-
lowed-up every 3 months in the first 2 years, every 6
months between 2-5 years. Each follow-up included a
complete examination, basic serum detection, chest X-
ray, and ultrasound of liver and abdomen. Endoscopy
was performed at every visit after treatment. MRI of the
head and neck areas was performed every 6 months.
PET was optional in high risk incident. Toxicities were
observed and scored according to the Toxicity criteria
of the Radiation Therapy Oncology Group (RTOG)
radiation morbidity scoring criteria at each follow-up
[24].
The primary endpoints were treatment compliance
and acute toxicities. The secondary endpoints of this
study were late toxicities, local recurrence-free survival
(LRF), regional recurrence-free survival (RRF), distant
metastasis-free survival (DMF), disease-free survival
(DFS) and overall survival (OS). Follow-up time was
ensured from the date of treatment initiation to the date
of the last contact or death. Time to failure was calcu-
lated from the date of treatment initiation to the date of
the relevant event. Survival analyses were computed
using the Kaplan-Meier method, P < 0.05 was consid-
ered significant. The analyses were performed with the
SPSS software package (Version 13.0, SPSS Inc., Chi-
cago, IL).
Results
Patterns of failure
The total numbers of death were 17 cases, including
tumor recurrence (3 patients), distant metastasis (9
patients), both recurrence and metastasis (5 patients).
Table 2 lists the patterns of failure. The overall failure
rate was 26.1% (36 patients): among these, 6 local recur-
rence, 4 regional recurrence, noticeable event was only 2
cases local/regional recurrence were marginal of field
radiation (Figure 1), 8 patients had inside-field
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(range, 4-23 months). There were 26 distant metastases
(18.8%), the most common metastasis site is bone. The
median distant metastasis time was 9.5 months (range,
3-23 months). Obviously, distant metastasis was the
major patterns of failure.
Toxicities
The IMRT plans showed decreased doses to normal
structures and increased doses to target volumes, which
might decreased the unwanted side effects. The acute
toxicities were listed in Table 3. The primary toxicities
were xerostomia, stomatitis, dermatitis and neutropenia,
which were generally mild or moderate. The total inci-
dence of grade 3 acute toxicities in patients received
IMRT plus chemotherapy was 22 patients (19.5%), sig-
nificantly higher than those received IMRT alone 2
patients (8,0%) (P < 0.05).
T h el a t et o x i c i t i e si n c l u d eG r a d eI Im u c o s i t i s3
patients (2.2%), Grade III mucositis 14 patients(10.1%),
Grade III xerostomia 16 patients (11.6%), Grade III leu-
cocytopenia 6 patients(4.3%).
No grade IV acute and late toxicities were detected.
Survival analysis
The median follow-up time was 23 months (range, 2-53
months). 3-year OS, LRF, RFS, MFS and DFS were
83.1%, 93.9%, 96.3%, 79.5% and 70%, respectively. Locor-
egional recurrences did tend to occur more frequently
in the first 2 years post-treatment, resulted in the 2-year
OS fall rapidly.
The value of various potential prognostic factors
include age, gender, stage and use of chemotherapy on
predicting local control, DMF, DFS, and OS rates were
evaluated. Univariate analysis of prognostic factors in
survival rates showed male, stage T or N, lymph node
biopsy and chemotherapy was not associated with local
control, DFS, MFS and OS; Anemia before radiotherapy
and age (≤ 50 vs. > 50) were found to be the indepen-
dent predictors for OS (P = 0.013, hazard ratio [HR]
4.33, 95% confidence interval [CI] 1.367~13.734; P =
0.001, hazard ratio [HR] 6.99, 95% confidence interval
[CI] 2.290~21.343). To adjust for the prognostic factors,
the Cox regression analysis confirmed the outcomes
(Figure 2, 3).
Table 2 Causes of failure
No. of patients
Site
n%
Relapse 10
local relapse 6 4.3
Regional relapse 4 2.9
Metastasis 26
Bone 12 8.9
Liver 2 1.5
Lung 6 4.4
Other location 2 1.5
Multiple location 4 2.9
Figure 1 Intensity modulated radiotherapy plan for
nasopharyngeal carcinoma. A: Before treatment; B: Failures were
marginal-field after treatment.
Table 3 Acute toxicities during treatment
Acute toxicities I (%) II (%) III(%)
Dermatitis 29(21.0) 20(14.5) 7(5.1)
Stomatitis 16(11.6) 8(5.8) 3(2.2)
Neutropenia 24(17.4) 13(9.4) 2(1.5)
xerostomia 28(21.1) 26(18.8) 12(8.7)
Figure 2 Kaplan-Meier estimate of anemia factorial survival for
nasopharyngeal carcinoma patients treated with intensity
modulated radiotherapy.
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nificant additive effect on local/regional control, 3-year
MFS, DFS, and OS rates in this group of patients with
advanced NPC, regardless of their T-classification or
nodal status, definitively treated with IMRT in multivari-
ate analysis (P > 0.05). Distant metastasis becomes the
main cause of treatment failure.
Discussion
NPC presents high sensitivity to radiation. Radiation
alone for early NPC can achieve relatively high cure
rate, however, it is disappointing for locally advanced
disease. In pattern of conventional 2 dimensional radio-
therapy, increasing evidences support concurrent che-
moradiation to be standard treatment strategy for locally
advanced NPC, its efficacy has been proven in a number
of randomized phase III trails and meta-analyses
[12,13,25]. However, it’s difficult to increase OS by these
arms.
IMRT has been demonstrated often to produce super-
ior dose distributions in terms of improved tumor cov-
erage and lower doses to normal tissues for a variety of
cancers originating in the NPC region. IMRT allows for
fine modulation of radiation intensity within each radia-
tion beam, which can achieve high dose in tumor with-
out overdosing the normal organs [16,17]. It has been
proven that IMRT techniques is superior to conven-
tional technique with respect to technical advantages,
local or regional control, critical organ sparing and
treatment outcomes [26]. IMRT has been proven excel-
lent in the NPC treatment, patients with at least 66.5
Gy to their target volumes had significantly less locore-
gional failure. The last randomized study showed that
IMRT with different chemotherapy sequence produced
similar outcomes in terms of OS, DFS, RFS and MFS
rates [19]. Similarly, thus excellent results and less toxi-
cities in our patients could be largely due to the IMRT
applied. However, an unimagined univariate analysis
showed that IMRT eliminated many independent prog-
nostic factors compared with conventional radiotherapy,
only age > 50 years and anemia before radiotherapy
were significantly associated with poor OS; Male, stage
T or N and lymph node biopsy was not associated with
RFS, DFS, MFS and OS. Multivariate analysis of prog-
nostic factors in survival rates showed the same results,
which implied IMRT did balance the effects of different
chemotherapy pattern. The results maybe benefit from
high dose distributing for tumor, and significant
improvement profited from the IMRT. Especially, che-
motherapy failed the independent prognostic factor,
which presented more different from many randomized
trials [1,13,14,27,28]. The present study implied concur-
rent and adjuvant chemotherapy provided no significant
additive effect on local/regi o n a lc o n t r o l ,M F S ,D F S ,a n d
OS rates in advanced NPC patients, regardless of their
T-classification or nodal status, definitively treated with
IMRT. A logical interpretability did bring IMRT into
prominence; Secondly likelihood attributed to small
sample size or nonrandom incident in present study;
Other perhaps tumor characteristic in Northwest China
represent the favorable prognosis compared with the
disease in Southeast China [26,29]. EBV and histological
types in Northwest are significant different from those
in Southeast China. Patients present high EBV infection
> 90% and major undifferentiated tumor in Southeast
China, and EBV is a well-established risk factor for NPC
[29] particularly in undifferentiated NPC [30]. Conver-
sely, the present study showed that the EBV infection
was only 15.9%, the undifferentiated NPC was only
26.8% and all patients with EBV-positive were undiffer-
entiated NPC, which implied EBV play an important
role in the aetiology of this NPC histological type. Per-
haps it caused the diversity prognosis of NPC between
Southeast and Northwest China. High EBV prevalence
in undifferentiated NPC prompts EBV should be a risk
and poor prognosis factor for NPC [31,32]. Even so, two
cases local/regional failures in the study were still mar-
ginal of field radiation, and failed to rescue by che-
motherapy, which prompted the marginal of field
should be considered carefully to broaden befittingly in
high-risk patients.
The present data investigated, for the first time in
Northwest China, the role of EBV in the aetiology of
Figure 3 Kaplan-Meier estimate of age factorial survival for
nasopharyngeal carcinoma patients treated with intensity
modulated radiotherapy.
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in the low-incidence areas rarely represented undifferen-
tiated carcinoma, which maybe include other nosogen-
esis, are different from Southeast China.
In summary, the present study showed NPC in North-
west China possesses remarkable different from NPC in
Northwest, primary distinction represent in aetiology,
pathology and prognosis. IMRT in Northwest China has
achieved excellent results as well as an acceptable acute
toxicity profile.
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